SRR26320091
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.450
- TGF_BETA_SIGNALING+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- ANGIOGENESIS+0.370
- NOTCH_SIGNALING+0.360
- APICAL_JUNCTION+0.320
- PROTEIN_SECRETION+0.320
- WNT_BETA_CATENIN_SIGNALING+0.310
- KRAS_SIGNALING_UP+0.300
- UV_RESPONSE_DN+0.300
Top 10 suppressed
- E2F_TARGETS-0.250
- SPERMATOGENESIS-0.240
- FATTY_ACID_METABOLISM-0.210
- BILE_ACID_METABOLISM-0.200
- CHOLESTEROL_HOMEOSTASIS-0.150
- KRAS_SIGNALING_DN-0.130
- TNFA_SIGNALING_VIA_NFKB-0.130
- UNFOLDED_PROTEIN_RESPONSE-0.120
- PEROXISOME-0.070
- XENOBIOTIC_METABOLISM-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG461 | — | — | 0.743 |
| 2 | TCGA-XF-AAMT-01A-11R-A42T-07 | — | — | 0.731 |
| 3 | TCGA-CQ-6224-01A-11R-1915-07 | — | — | 0.731 |
| 4 | BSR_03_0053_A6_S70 | — | A | 0.725 |
| 5 | TCGA-FD-A3SP-01A-31R-A22U-07 | — | — | 0.723 |
| 6 | SRR26320064 | — | — | 0.722 |
| 7 | SRR2932815 | — | — | 0.716 |
| 8 | R42 | — | — | 0.715 |
| 9 | TCGA-DK-A1AB-01A-11R-A13Y-07 | — | — | 0.714 |
| 10 | TCGA-86-8055-01A-11R-2241-07 | — | cohortA1 | 0.713 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.450 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.360 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |